Search details
1.
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
Clin Trials
; 20(6): 699-707, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37489819
2.
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 8: e2300527, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38603652
3.
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; : JCO2302078, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38748939
4.
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 8: e2300513, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38354330
5.
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200505, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36753688
6.
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300041, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37315265
7.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; 41(33): 5140-5150, 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-37561967
8.
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200609, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37027810
9.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300385, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-38096472
10.
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 7: e2300279, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-38039429
11.
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
JCO Precis Oncol
; 6: e2200306, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36315917
12.
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 6: e2200191, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36409971
13.
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
J Clin Oncol
; 39(22): 2443-2451, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-33844595
14.
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol
; 15(6): 743-750, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33068284
15.
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 4: 757-766, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-35050752
16.
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol
; 15(6): 733-741, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33090333
17.
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 3: 1-8, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-35100714
18.
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 20182018.
Article
in English
| MEDLINE | ID: mdl-30603737
Results
1 -
18
de 18
1
Next >
>>